INS and metabolic dysfunction-associated steatotic liver disease: Treatment with RES reversed the impaired glucose tolerance and increased plasma insulin and nesfatin-1 levels of NAFLD rats (P < 0.05 or P < 0.01) but had no effect on the plasma leptin level.